Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

672.50
-4.9503-0.73%
Number of Gainers:47
Number of Losers:95
Number of Flat:11
PE:- -
High:682.02
Open:677.19
Low:671.55
Close:677.28
Volume:85.30M
Turnover:2.87B
Market Cap:463.33B
Float Cap:353.57B

Loading ...

Press Release: Title Resources Group Appoints Brian Ruzycki as Chief Technology Officer

Dow Jones
·
Sep 28

AMC Token Surges Ninefold: How Wrapped and Issuer-Sponsored Tokens Jointly Build an Arbitrage Market

Stock News
·
Sep 28

Phillips Edison is Maintained at Equal-Weight by Barclays

Dow Jones
·
Sep 28

Dow Jones Top Company Headlines at 9 am ET: Nvidia Adds Record $150 Billion to Stock Buyback | Citi ...

Dow Jones
·
Sep 28

Truist Financial Sticks to Their Hold Rating for Oklo Inc (OKLO)

TIPRANKS
·
Sep 28

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and Agilon Health (AGL)

TIPRANKS
·
Sep 28

Moving iMage Q4 Revenue USD 4.545 Million

Reuters
·
Sep 28

Moving iMage FY26 Net Loss Narrows 69% to USD 297,000; Net Sales Fall 4.6% to USD 17.32 Million

Reuters
·
Sep 28

Moving Image Q4 Net Income USD -296 Thousand

THOMSON REUTERS
·
Sep 28

Market Chatter: Citi Taps Coinbase to Enable Stablecoin Payments for Clients

MT Newswires Live
·
Sep 28

SHF Holdings announces board approved 1-for-12 reverse stock split

TIPRANKS
·
Sep 28

Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial

TIPRANKS
·
Sep 28

Phillips Edison Schedules Third-Quarter Earnings Conference Call

Reuters
·
Sep 28

TransCode Says Phase 1a Trial Shows 71.4% Stable Disease Rate for TTX-MC138 in Advanced Solid Tumors

Reuters
·
Sep 28

Transcode Reports Continued Disease Stabilization and Extended Treatment Duration with Ttx-Mc138 in Ongoing Phase 1a Clinical Trial Follow-up

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - Three Patients Remain Progression-Free at One Year

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - no Dose-Limiting Toxicities Reported Across Evaluated Dose Levels

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - 57.1% Disease Control Rate Through Three Months of Therapy

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - 71.4% Stable Disease Rate in 14 Efficacy-Evaluable Patients

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - Primary Endpoint of Phase 1a Study Met

THOMSON REUTERS
·
Sep 28